Prognostic significance of locally invaded sites and tissue types in patients with nasal extranodal natural-killer/T-cell lymphoma: a single-center retrospective analysis
Extranodal natural killer/T-cell lymphoma (ENKTL), nasal type, is an aggressive form of non-Hodgkin lymphoma that primarily affects the upper part of the throat and nose. While doctors use tools like the International Prognostic Index (IPI) to predict outcomes, these tools often fall short for patients in the early stages (I/II) who have extensive local tumor growth. A 2019 study from Beijing Tongren Hospital and Capital Medical University aims to fill this gap by exploring how the specific sites of local tumor invasion affect survival in ENKTL patients.
What is ENKTL?
ENKTL is a rare but aggressive type of non-Hodgkin lymphoma—a cancer of the lymphatic system. Unlike many lymphomas that start in lymph nodes, ENKTL is extranodal, meaning it begins in organs or tissues outside the lymph nodes—most commonly in the upper aerodigestive tract (the nose, nasopharynx, or oropharynx). It’s strongly associated with the Epstein-Barr virus (EBV) and often shows an angiodestructive growth pattern—damaging blood vessels and causing tissue death (necrosis). Even though most patients are diagnosed early, 5-year survival rates range from just 42% to 60%, and there’s no standard treatment for advanced or relapsed cases.
The Study: Who, How, and Why
The study, led by Dr. Hong-Gang Liu and colleagues from the Department of Pathology at Beijing Tongren Hospital (Capital Medical University), analyzed data from 86 patients diagnosed with ENKTL between June 2002 and April 2016. All patients had:
- A confirmed diagnosis by two pathologists (using the 2008 World Health Organization [WHO] classification).
- Detailed clinical and follow-up records.
- Imaging results (PET/CT, CT, or MRI) to assess how the tumor had invaded nearby structures, soft tissues, or bones.
The team used retrospective analysis—looking back at existing data—to answer a key question: Does the location of local tumor invasion affect survival in ENKTL patients? They used statistical tools like Kaplan-Meier curves (to compare survival rates between groups) and Cox regression analysis (to identify independent predictors of survival, adjusting for factors like age, stage, and treatment).
All patients received primary treatment with chemotherapy (either anthracycline or asparaginase-based), and 55 (63.5%) also had radiotherapy. The median follow-up time was 28.6 months (range: 1–118 months).
Key Findings: Where the Tumor Spreads Matters Most
The results revealed that not all local invasion is equal—survival depends on which sites the tumor invades, not just whether it has spread:
1. Adjacent Structures vs. Critical Sites
Most patients (82.6%) had tumor growth into adjacent structures—nearby areas like the nasopharynx (upper throat behind the nose), sinuses, or tonsils. Surprisingly, this general spread didn’t affect survival. However, if the tumor invaded critical sites like the eyeball (4.7% of patients) or brain (3.5%), 2-year survival rates dropped sharply:
- 50% for eyeball involvement (vs. 71% for no involvement).
- 33% for brain involvement (vs. 71% for no involvement).
2. Soft Tissue Invasion Is a Major Red Flag
A quarter of patients (25.6%) had tumor growth into soft tissues (muscles, skin, or eyelids). These patients had a much lower 2-year survival rate (43%) than those without soft tissue involvement (74%). Two sites stood out as particularly dangerous:
- Cheek or facial muscles: 16.3% of patients had involvement here, with a 2-year survival rate of just 36% (vs. 76% for no involvement).
- Eyelids: 10.5% of patients had eyelid involvement, with a 2-year survival rate of 34% (vs. 74% for no involvement).
3. Bone Invasion Signals Poor Outcomes
Nearly a third of patients (30.2%) had bone destruction or erosion (damage to bones like the maxilla, skull base, or orbit). Those with bone involvement had a 52% 2-year survival rate—compared to 72% for those without. The most dangerous bone sites were:
- Maxilla: The upper jawbone (7.0% of patients). 2-year survival was just 33% (vs. 73% for no involvement).
- Skull base: The bone at the bottom of the skull (5.8% of patients). 2-year survival was 40% (vs. 72% for no involvement).
4. Independent Predictors of Survival
When the team adjusted for other factors (age, stage, treatment), two sites emerged as independent predictors of lower 2-year survival:
- Cheek or facial muscle involvement: Patients with this had a 5.5 times higher risk of death than those without.
- Maxilla bone involvement: Patients with this had a 6.1 times higher risk of death than those without.
What This Means for Patients and Doctors
These findings fill a critical gap in ENKTL care. Current prognostic tools like the International Prognostic Index (IPI) don’t account for local invasion sites—so they often fail to identify early-stage patients at high risk of poor outcomes. This study changes that by:
1. Helping Doctors Identify High-Risk Patients
A patient with cheek muscle or maxilla involvement might need more aggressive treatment (e.g., combination chemotherapy and radiotherapy) or closer monitoring to catch recurrence early. For example, a patient with maxilla bone involvement could benefit from targeted therapy or stem cell transplantation if standard treatments aren’t working.
2. Highlighting the Role of Imaging
Imaging techniques like PET/CT, CT, and MRI were essential for detecting these high-risk invasions. This underscores the importance of early, detailed imaging in ENKTL diagnosis—catching these sites early can mean better treatment decisions and outcomes.
3. Empowering Patients
For patients, this study means a more personalized prognosis. Instead of a one-size-fits-all “early-stage” label, doctors can say: “Your tumor has invaded the cheek muscle—we need to watch this closely.” This transparency helps patients and families make informed decisions about their care.
Limitations to Consider
Like all studies, this one has limitations:
- Single-center, small cohort: The results are based on 86 patients from one hospital. Larger, multicenter studies are needed to confirm these findings in more diverse populations.
- Retrospective design: Retrospective studies rely on existing data, which can introduce bias (e.g., differences in how patients were treated over time).
- Shorter follow-up: The median follow-up time (28.6 months) is shorter than ideal for long-term survival analysis.
Conclusion: Precision Prognosis for ENKTL
This study adds critical nuance to our understanding of ENKTL. By showing that specific local invasion sites—not just the fact of invasion—drive survival outcomes, it gives doctors a more precise tool to guide treatment. For patients, this means better odds of getting the right care at the right time.
The takeaway? For ENKTL, where the tumor spreads is just as important as if it spreads. With this knowledge, doctors can move closer to personalized medicine for this aggressive lymphoma—improving outcomes and giving patients more hope.
Prognostic significance of locally invaded sites and tissue types in patients with nasal extranodal natural-killer/T-cell lymphoma: a single-center retrospective analysis
Ge-Hong Dong1,2,3, Yong Li4, Ji-Yong Dong4, Xue Li1, Hong-Fei Wan2,3, Lei Yang5, Jing-Wen Wang5, Li-Ping Gong6, Yi-Hua Zhao2,3, Hong Zhang2,3, Zi-Fen Gao1, Hong-Gang Liu2,3
1Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China; 2Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; 3Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Capital Medical University, Beijing 100730, China; 4Department of Radiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; 5Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; 6Department of Pathology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China.
Published in Chinese Medical Journal (2019;132(11):1305–1313). doi.org/10.1097/CM9.0000000000000263
Was this helpful?
0 / 0